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analysis indicted that the number of SLNs removed was 
influenced only in cases where the operating surgeon had 
performed more than 20 laparoscopic ICG SLN mappings.
Conclusions A higher SLN count does not seem to increase 
the accuracy of SLN mapping in cervical and endometrial 
cancer patients.
Keywords Endometrial cancer · Cervical cancer · Sentinel 
lymph node mapping · Indocyanine green · Sentinel lymph 
node count · Echelon lymph nodes
Background
Lymph nodal status is one of the most important prognostic 
factors driving adjuvant treatment of cervical and endome-
trial cancer. In early-stage cervical cancer, the presence of 
metastatic lymph nodal disease is regarded as a high-risk 
pathologic factor associated with a poorer survival rate 
and indicating the need for adjuvant chemoradiotherapy 
(Delgado et al. 1990; Peters et al. 2000). In endometrial 
cancer, despite the fact that two randomized trials failed 
to show any benefit of a lymphadenectomy, surgical stag-
ing was never abandoned, but rather tailored on the basis 
of intrauterine risk factors evaluated on intraoperative fro-
zen section (Benedetti Panici et al. 2008; ASTEC Study 
Group et al. 2009; Kumar et al. 2012; Sala et al. 2014; 
Papadia et al. 2009; Morotti et al. 2012; Laufer et al. 
2013). Although adjuvant treatment may be considered in 
node negative patients with pathologic risk factors in the 
uterus, such as LVSI, lymph nodal status is a fundamen-
tal factor in the decision to recommend further treatment 
after surgery (Simpkins et al. 2013; Colombo et al. 2016). 
Recently, NCCN guidelines have recognized SLN mapping 
as an acceptable alternative to surgical staging in clinically 
Abstract 
Purpose The adoption of a sentinel lymph node (SLN) 
algorithm and the presence of high bilateral detection rates 
have been associated with increased accuracy of SLN map-
ping in cervical and endometrial cancer patients. In this 
context, the significance of the number of SLNs removed 
has not yet been investigated. The aim of this study was to 
evaluate (a) whether or not a higher SLN removal count 
is associated with a reduced false-negative rate and (b) 
which clinical factors correlate with the number of SLNs 
removed.
Methods Patients with cervical or endometrial cancer who 
underwent SLN mapping with bilateral SLN detection fol-
lowed by lymphadenectomy were evaluated retrospectively. 
On the basis of the mean number of the SLNs removed, 
the patients were divided in two groups: Group 1 included 
patients with up to 3 SLNs removed and Group 2 included 
patients with more than 3 SLNs removed. Factors predict-
ing a higher SLN count were evaluated using univariate and 
multivariate analysis.
Results Eighty-four patients met the inclusion criteria. 
The two groups consisted of 42 patients each and differed 
only by the median SLN count. Two endometrial cancer 
patients in Group 1 had false-negative pelvic SLNs and iso-
lated para-aortic metastases; no false-negative SLNs were 
recorded in Group 2 (p = n.s.). The results of multivariate 
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localized cervical and endometrial cancer patients (NCCN 
Guidelines 2015). Furthermore, the introduction of indocy-
anine green (ICG) as a tracer in conjunction with dedicated 
robotic and laparoscopic platforms seems to have signifi-
cantly increased the bilateral detection rates and the “user-
friendliness” of the SLN mapping in these cases (Imboden 
et al. 2015; Papadia et al. 2016; Tanner et al. 2015; How 
et al. 2015; Buda et al. 2016). We have previously reported 
high overall and bilateral detection rates and low false-pos-
itive rates in patients with cervical and endometrial cancer 
undergoing ICG SLN mapping (Imboden et al. 2015; Papa-
dia et al. 2016).
Potential advantages of SLN mapping include the iden-
tification of lymph nodes located in unusual anatomic loca-
tions that would have not been removed otherwise and 
pathologic ultrastaging that allows for the identification of 
a small burden of metastatic disease that may have other-
wise remained undetected. Furthermore, as opposed to a 
full lymphadenectomy, an SLN biopsy has been associated 
with reduced postoperative morbidity (Veronesi et al. 2003; 
Van der Zee et al. 2008). The single most important char-
acteristic of the SLN is its false-negative rate, which has to 
be low in order to avoid the risk of undertreating a patient, 
thereby compromising her survival.
The SLN is defined as the first lymph node to receive 
lymphatic drainage from a tumor. However, especially if 
a combination of tracers (such as 99Tc and blue dyes) or 
ICG (which is transported rapidly in the lymphatic vessels 
and has a long half-life) are used, multiple SLNs are often 
identified. Although additional lymph nodes other than the 
SLN should be considered as echelons, it is not always 
easy to distinguish clearly between the two. The removal of 
additional SLNs may reduce the benefit of the SLN map-
ping. On the other hand, the removal of all the lymph nodes 
draining the tracer may increase the safety of the procedure 
by reducing the false-negative rate.
The aim of the study is to evaluate whether or not a spe-
cific number of SLNs removed is associated with a reduced 
false-negative rate and which clinical factors correlate with 
the number of SLNs removed.
Materials and methods
A retrospective analysis of patients with complex atypi-
cal endometrial hyperplasia (CAH) and clinical stage I 
and II cervical or endometrial cancer undergoing ICG 
SLN mapping at our Institution between December 2012 
and January 2016 was conducted. Data on a subset of the 
patients in this cohort were previously published (Imboden 
et al. 2015; Papadia et al. 2016). Patients with CAH were 
included in the study because of the documented high risk 
of harboring endometrial cancer (Morotti et al. 2012). For 
the purpose of the study, only patients in whom the SLN 
mapping was successful bilaterally (patients who mapped 
in both hemipelvises) and in whom a pelvic lymph nodal 
dissection (PLND) and/or para-aortic lymph nodal dissec-
tion (PALND) was performed after having removed the 
SLNs were selected. Demographic, clinical, and pathologic 
data were retrieved retrospectively from an electronic data-
base. Data on SLN mapping were collected prospectively. 
The study was IRB approved. All patients signed informed 
consent.
In every case, SLN mapping was performed as follows: 
after a diagnostic laparoscopy, the cervix was injected 
submucosally, one centimeter deep in the stroma at the 
four cardinal points, with a total of 8 ml ICG. Two vials 
of 25 mg ICG powder (Pulsion®) had each been previously 
suspended with 5 ml sterile water. After injection of the 
tracer, the pelvic peritoneum was opened and the camera 
mode was switched on NIR mode to detect the fluorescent 
signal and thereby the SLNs. Additionally, any clinically 
suspicious node was removed.
The management differed among patients with cervi-
cal cancer and patients with endometrial cancer or CAH. 
For cervical cancer patients, the SLNs removed as well as 
the clinically suspicious non-SLNs (NSLNs) were sent to 
frozen section analysis. If the SLNs and NSLNs removed 
were negative for metastatic disease, the planned surgical 
procedure was completed in patients with early-stage cervi-
cal cancer. If metastatic disease was involved in the SLNs 
and NSLNs that were removed, the radical procedure was 
aborted in favor of concurrent chemo-radiotherapy. In the 
latter cases, a laparoscopic para-aortic lymph node dissec-
tion was performed to determine the extension of the radia-
tion fields.
For patients with endometrial cancer or CAH, frozen 
section analysis of the SLNs was not performed routinely, 
but only if the SLNs appeared clinically suspicious for met-
astatic involvement. NSLNs that appeared macroscopically 
suspicious were removed and sent for frozen section. In the 
event of metastatic disease in the lymph nodes, a complete 
pelvic and para-aortic lymphadenectomy (PPALND) was 
performed. In the other cases, following the completion of 
the total laparoscopic hysterectomy, the uterus was sent to 
frozen section. Based on identification of tumor risk factors 
and clinical judgment, a laparoscopic PLND or PALND or 
both were performed. In every case, using final histopatho-
logical analysis, a complete ultrastaging of the SLNs was 
performed (three slides H&E 200um, immunohistochemis-
try (IHC) if negative).
The false-positive rate was defined as zero. The over-
all detection rate was calculated by dividing the number 
of procedures in which at least one SLN was identified 
by the total number of procedures performed. A true-pos-
itive SLN was defined as a positive SLN identified with 
1833J Cancer Res Clin Oncol (2016) 142:1831–1836 
1 3
histopathological techniques (HE, serial sectioning, IHC), 
independent of regional lymph node status. A false-nega-
tive SLN mapping was defined as a bilateral negative SLN 
in combination with a metastatic NSLN.
Following the calculation of the median number of SLNs 
removed per patient, the cohort of patients was divided into 
two groups: Group 1 included patients with a lymph node 
count below the median number of removed SLNs; Group 
2 included patients with a lymph node count above the 
median number of removed SLNs. Demographic and clini-
cal characteristics of the two groups were compared using 
an unpaired t test. The false-negative rates among the two 
groups were compared using Fischer’s exact test. Univariate 
and multivariate analyses were performed in order to iden-
tify factors predicting a higher number of SLNs removed. 
Multivariable models were carried out for variables with a p 
value <0.2 in univariate analysis. p values ≤0.05 were con-
sidered statistically significant. Statistical analysis was per-
formed using IBM-Microsoft SPSS version 22.0.
Results
During the study period, 131 patients with CAH, endome-
trial cancer, or cervical cancer underwent ICG SLN map-
ping. Data on overall and bilateral detection rates and 
false-negative rates were previously reported, separately for 
cervical and endometrial cancer patients from this cohort 
(Imboden et al. 2015; Papadia et al. 2016). Of these patients, 
84 met study inclusion criteria (bilateral detection rate and 
full PPALND). The median number of sampled SLNs was 
3.5 (range: 2-18). Based on this result, two groups of patients 
were created. Group 1 consisted of 42 patients with an SLN 
count of up to 3 lymph nodes and Group 2 consisted of 42 
patients with a SLN count of 4 or more. Basic clinical and 
demographic characteristics did not differ between the two 
groups for age, BMI, type of cancer (cervical or endome-
trial), and mean pelvic and para-aortic NSLN count. The two 
groups differed only in the median SLN count (2 for Group 1 
vs 5 for Group 2). Nine patients in Group 1 (21.5 %) and 12 
patients in Group 2 (28.6 %) had metastatic SLNs (p = n.s.). 
Eight patients in Group 1 (19 %) and 12 patients in Group 2 
(28.6 %) had metastatic NSLNs in (p = n.s.). Patient charac-
teristics are summarized in Table 1.
In two endometrial cancer patients, both in Group 1, the 
SLNs were false negative. Two SLNs in one patient and 
three SLNs in the other patient were identified in the pelvis. 
In both patients, the SLNs and the pelvic NSLNs were neg-
ative, whereas one metastatic para-aortic NSLN was identi-
fied in one patient at the time of the final histopathologi-
cal analysis, and two in the other patient. No false-negative 
SLNs were identified in Group 2. The SLN false-negative 
rate was 4.8 and 0 % for Group 1 and Group 2, respectively 
and did not differ significantly between the two groups 
(Table 2).
Patient characteristics (age, BMI), disease characteris-
tics (type of tumor, presence of positive SLNs), and char-
acteristics of the surgeon (experience of up to or over 20 
ICG SLN and gynecologic oncology certification) were 
evaluated for influence on the SLN count. In the univariate 
analysis, the BMI of the patient, type of cancer (cervical vs 
endometrial), positive SLNs, surgical experience (up to 20 
procedures vs over 20 procedures), and gynecologic oncol-
ogy certification were considered significant and further 
analyzed at multivariate analysis. Only surgical expertise 
maintained significance as an independent prognostic fac-
tor for number of SLNs removed. Data on univariate and 
multivariate analysis are presented in Table 3.
Discussion
In the past decade, through the adoption of minimally inva-
sive approaches and more recently through the acceptance 
Table 1  Clinical and demographic characteristics of the patients
Patients in Group 1 and 2 differed only for median SLN count
Characteristics Group 1 (n = 42) Group 2 (n = 42) p
Age (years) 54.5 (34–89) 55 (28–83) 0.6
BMI (kg/m2) 25.6 (17.4–43.6) 44.9 (19–40.2) 0.8
Histologic diagnosis 0.01
 Endometrial cancer 25 (1 CS) 20
 Cervical cancer 17 22
 Median number of 
SLNs
3 (2–3) 5 (4–18) <0.001
 Patients with meta-
static SLNs
9 (21.4 %) 12 (28.6 %) 0.3
Median number of 
pelvic LN
27 36 0.2
Median number of 
para-aortic LN
12 (21 pts) 20.5 (28 pts) 0.21
Pts with metastatic 
pelvic NSLN
8 (19 %) 12 (28.6 %) 0.17
Metastatic para-aortic 
NSLN
6 (14.3 %) 4 (9.5 %) 0.24



















≤3 42 9 2 4.8
>3 42 12 0 0
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of SLN mapping as an alternative to a full lymphadenec-
tomy, the management of early-stage cervical and endome-
trial cancer has changed significantly (NCCN Guidelines 
2015; Papadia et al. 2004; Walker et al. 2009; Ditto et al. 
2015a, b). Since the introduction of ICG as a tracer and the 
availability of robotic and laparoscopic platforms for SLN 
mapping, this technique has gained widespread use, as 
documented in the large volume of literature on this topic. 
The majority of the literature deals with detection rates 
and false-negative rates of the SLN mapping (Imboden 
et al. 2015; Papadia et al. 2016; Tanner et al. 2015; How 
et al. 2015). We have shown previously that ICG SLN 
mapping yields higher bilateral detection rates than com-
bined 99Tc and patent blue SLN mapping in cervical cancer 
patients, with overall and bilateral detection rates of 95.5 % 
(Imboden et al. 2015). In endometrial cancer, we recorded 
overall and bilateral detection rates of 96 and 88 %, respec-
tively, in 75 patients undergoing ICG SLN mapping (Papa-
dia et al. 2016). However, no one has focused thus far on 
how many SLNs need to be removed for the mapping to be 
oncologically safe.
In our series, the median number of SLNs removed 
per patient was 3.5. The SLNs were false negative in two 
patients with endometrial cancer. These data compare 
favorably with those of Barlin et al., who reported a decline 
in their false-negative rate from 15 to 2 % after applying an 
SLN mapping algorithm (Barlin et al. 2012). Furthermore, 
the false-negative SLN rate did not differ significantly 
between the groups of patients with a lower or higher SLN 
count. Interestingly, the two patients in whom the false-
negative SLNs were identified had isolated para-aortic 
metastases, in one and two lymph nodes, respectively, with 
negative pelvic SLNs and negative pelvic NSLN. These 
data are in line with the risk of isolated para-aortic metas-
tasis reported by Mariani el al in fully staged high-risk 
EMCA patients (Kumar et al. 2014). In these cases, sam-
pling a larger number of nodes would have probably not led 
to the identification of these metastatic lymph nodes. It is 
unclear whether or not a hysteroscopic peritumoral tracer 
injection would have facilitated the identification of these 
lymph nodes; so far, the cervical tracer injection remains 
the preferred method for SLN mapping in endometrial can-
cer (Ditto et al. 2015a, b; Bogani et al. 2015).
When performing a SLN biopsy, the surgeon has to 
weigh the risks of dissecting as many lymph nodes as in the 
case of a full lymphadenectomy against the risk of miss-
ing a metastatic lymph node. One of the characteristics of 
ICG is that it travels relatively quickly through the lym-
phatic vessels. However, in comparison with blue dyes, the 
detection of which practically disappears after 30 min, the 
fluorescent signal of ICG remains in the lymph nodes for a 
longer time. This may lead to the identification of several 
fluorescent lymph nodes, and at times it may be difficult 
to distinguish between a true SLN that is draining an inde-
pendent lymphatic vessel and an echelon lymph node that 
has drained the tracer after it travelled through a real SLN. 
In cases when a significant amount of time elapses between 
the intracervical injection and the retroperitoneal explora-
tion, such as when a prolonged adhesiolysis is needed, mul-
tiple lymph nodes may appear fluorescent.
The question of how many SLNs to remove is not a 
new one. This topic has been investigated in breast can-
cer surgery with heterogeneous results. It is recommended 
that after 99Tc tracer injection, every SLN with a CPM of 
more than 10 % of the “hottest” node be removed (Martin 
et al. 2000). Some authors suggested that when a combi-
nation of 99Tc and blue dyes is used, removing more than 
four SLNs does not impact significantly on the accuracy 
of the mapping (Zakaria et al. 2007; Goyal et al. 2006; 
McCarter et al. 2001; Woznick et al. 2006; Chagpar et al. 
2007; Vaidya et al. 2005). In breast cancer surgery, the 
removal of five or more SLNs is associated with higher 
rates of axillary seroma and wound infection (Wilke et al. 
2006).
Table 3  Univariate and multivariate analysis on factors possibly influencing SLN count
Bold values indicates that significant for the multivariate analysis of p value is less than 0.05
Age of the patient, BMI, type of tumor (endometrial vs cervical) and surgeon’s expertise did not significantly influence the SLN count
Univariate analysis Multivariate analysis
b (SE) β p b (SE) β p
Age in years −0.026 (0.021) −0.131 0.234 0.004 (0.027) 0.021 0.876
BMI in kg/m2 −0.083 (0.052) −0.175 0.112 −0.045 (0.055) −0.094 0.414
Type of cancer (endometrial vs cervical) 1.188 (0.674) 0.191 0.081 0.596 (0.875) 0.096 0.498
Hx of pelvic surgery (yes vs no) 0.005 (0.834) 0.001 0.995
Surgical expertise (≤ vs >20 performed procedures) 1.918 (0.656) 0.307 0.004 1.476 (0.726) 0.236 0.046
Gynecologic oncology certification (no vs yes) 1.565 (0.748) 0.225 0.040 0.711 (0.808) 0.102 0.381
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It is common that more than one SLN is identified in 
each patient. In a multicenter validation trial in melanoma, 
an average of 2.8, 2.3 and 2.6 SLNs were removed from the 
axilla, groin and neck, respectively (Morton et al. 1999). 
This may reflect the passing through of dye from the “true” 
SLN into secondary echelon nodes, or simply normal ana-
tomical variation in which the lymphatics of a given site 
drain simultaneously to more than one SLN.
Our results indicate that removal of more than 3 senti-
nel lymph nodes does not affect the accuracy of the SLN 
mapping. Therefore, we do not want to set an upper limit 
to the number of SLNs that should be sampled, but rather 
highlight the fact that removing all stained lymph nodes 
may not necessarily improve the accuracy of the SLN map-
ping. ICG has a long half-life and remains in the lymphatic 
system for a long time. If we wait long enough after tracer 
injection, the SLNs and the echelons lymph nodes drain-
ing the SLNs will all uptake the tracer and stain fluores-
cent. In these cases, an SLN mapping may translate eas-
ily into a focused sampling or even into a complete 
lymphadenectomy.
We then tried to assess the influence of a patient charac-
teristics (age, BMI), tumor characteristics (type of tumor, 
presence of metastatic SLNs), and the surgeon’s expertise 
(gynecologic oncology certification, number of procedures 
performed) on the number of removed SLNs using univari-
ate and multivariate analysis. In multivariate analysis, the 
number of removed SLNs correlated only with the number 
(more that 20) of laparoscopic ICG SLN mappings per-
formed by the operating surgeon. Gynecologic oncology 
certification was not an independent variable affecting SLN 
count. With greater specific experience in ICG SLN map-
ping, surgeons may be more confident in their ability to 
correctly discern SLNs from echelon nodes, leading to the 
removal of a smaller number of nodes. These data correlate 
well with what is considered to be the learning curve for 
SLN mapping in breast cancer (McMasters et al. 2001).
Other factors that may influence the number of SLNs 
identified are the concentration and volume of ICG 
injected. In our institution, we inject a volume of 8 ml of 
ICG solution at a concentration of 5 mg/ml for a total of 
40 mg of ICG. This dose is significantly higher than the 
dose used by other authors, who typically inject a total of 
2 ml at a concentration of 1.25 mg/ml (Ruscito et al. 2016; 
Buda et al. 2016). We were unfortunately unable to assess 
the influence of the volume and concentration of ICG solu-
tion injected on the number of SLNs removed, since the 
amount of ICG solution used in every patient was identical.
Limitations of the study include its retrospective nature 
and the relatively small sample size. On the other hand, the 
prospective SLN mapping data collection and the inclusion 
of patients who mapped bilaterally only and were surgi-
cally staged corroborate the strengths of the study. To our 
knowledge, this is the first series that seeks to identify an 
optimal number of SLNs removed. Although for every SLN 
that drains, an independent lymphatic vessel should be 
sampled. In our experience, removing more than 3 SLNs 
did not increase the accuracy of the SLN mapping.
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